Pharmaco - Articles
Learn about new methods and innovative tools to help you with your translational research.
As you know, translational research is a crucial bridge between pre-clinical and clinical trials for CNS diseases. Its value is determined by how well it can map a drug’s physiological effects and predict the likelihood that it will be successful in clinical trials. Consequently, the better and more precise the translational research, the more money will be saved during drug development and the quicker a drug can successfully reach market. Since translational research is bi-directional in nature, working from the laboratory to the clinic, and from the clinic back to the laboratory, it is inherently collaborative. To h…
As you know, translational research is a crucial bridge between pre-clinical and clinical trials for CNS diseases. Its value is determined by how well it can map a drug’s physiological effects and predict the likelihood that it will be successful in clinical trials. Consequently, the better and more precise the translational research, the more money will be saved during drug development and the quicker a drug can successfully reach market. Since translational research is bi-directional in nature, working from the laboratory to the clinic, and from the clinic back to the laboratory, it is inherently collaborative. To h…
Limitations in the ability to optimize dose modification within the clinical trial setting represents a serious bottleneck in the drug development process. This barrier increases development time, causes the unnecessary early termination of valuable candidates and adds up to $300 million/drug in costs. Petra Biotek are set to knock down these barriers through their computer-based Cycle Dose Modification system. The positive impact that this technology is expected to have on the clinical developm
[] : Limitations in the ability to optimize dose modification within the clinical trial setting represents a serious bottleneck in the drug development process. This barrier increases development time, causes the unnecessary early termination of valuable candidates and adds up to $30…
[] : Limitations in the ability to optimize dose modification within the clinical trial setting represents a serious bottleneck in the drug development process. This barrier increases development time, causes the unnecessary early termination of valuable candidates and adds up to $30…
27-Aug-2010
Treatment with combined estrogen/progestin doubles the risk of VTE in post-menopausal women and for obese women the risk is even higher, a recent study showed. However millions of women no longer taking HRT remain at risk of osteoporosis, which presents a huge market opportunity for non-hormonal classes in treating and preventing osteoporosis.
The final data on the incidence of venous thromboembolism (VTE) in the Womens Health Initiative Estrogen Plus Progestin clinical trial was published this month in the Journal of the American Medical Association. The aim of the trial, part of a 15 year program to investigate morbidity and mortality in women that started in 1991, was to determine whether hormone replacement therapy with combined estrogen and progestin may offer some cardioprotection t…
The final data on the incidence of venous thromboembolism (VTE) in the Womens Health Initiative Estrogen Plus Progestin clinical trial was published this month in the Journal of the American Medical Association. The aim of the trial, part of a 15 year program to investigate morbidity and mortality in women that started in 1991, was to determine whether hormone replacement therapy with combined estrogen and progestin may offer some cardioprotection t…
27-Aug-2010
Healthcare professionals in the UK are already experiencing the benefits of being able to view this extensive product and disease-based resource online at a time and place that is convinient to them
Built by PharmiWeb Solutions on behalf of AstraZeneca in the , The Nexium GP Resource is an exciting new audio visual resource intended as an aid to decision making in the management of reflux disease and appropriate prescribing of NEXIUM® (esomeprazole). To read more about NEXIUM, view the prescribing information by clicking here. This is an innovative way for AstraZeneca to provide educational resources and communicate product and disease information to busy healthcare professionals in a format and at a time that is convenient to them. Features of this resource include: · &n…
Built by PharmiWeb Solutions on behalf of AstraZeneca in the , The Nexium GP Resource is an exciting new audio visual resource intended as an aid to decision making in the management of reflux disease and appropriate prescribing of NEXIUM® (esomeprazole). To read more about NEXIUM, view the prescribing information by clicking here. This is an innovative way for AstraZeneca to provide educational resources and communicate product and disease information to busy healthcare professionals in a format and at a time that is convenient to them. Features of this resource include: · &n…
Peripheral arterial disease (PAD), caused by systemic atherosclerosis, is vastly underappreciated despite its abysmal mortality rates. With 5 and 10-year rates of 30% and 50% respectively mortality due to PAD is greater than that caused by coronary artery disease and stroke and is exceeded only by colorectal cancer. Better use of the pharmacological and interventional treatments available would dramatically improve the lives of the millions of PAD patients while at the same time ballooning the r
Peripheral arterial disease (PAD), caused by systemic atherosclerosis, is vastly underappreciated despite its abysmal mortality rates. With 5 and 10-year rates of 30% and 50% respectively mortality due to PAD is greater than that caused by coronary artery disease and stroke and is exceeded only by c…
Peripheral arterial disease (PAD), caused by systemic atherosclerosis, is vastly underappreciated despite its abysmal mortality rates. With 5 and 10-year rates of 30% and 50% respectively mortality due to PAD is greater than that caused by coronary artery disease and stroke and is exceeded only by c…
27-Aug-2010
Recruitment is a very inexact science – the statistics in favour of making the right decision based on the traditional interview alone are horrifyingly low (the percentage is in single figures). This is a fact that has really only been acknowledged in recent years and, as a result, organisations have looked for ways to improve the success rate of their selection choices.
Assessment centres have their origins in the military where they were used in training and development. The idea was then adopted by large commercial organisations, which used them as part of graduate recruitment programmes. However, the emergence of competency based selection, over the last 20 years or so, has brought the assessment centre into more common usage amongst serious recruiters. What is an…
Assessment centres have their origins in the military where they were used in training and development. The idea was then adopted by large commercial organisations, which used them as part of graduate recruitment programmes. However, the emergence of competency based selection, over the last 20 years or so, has brought the assessment centre into more common usage amongst serious recruiters. What is an…
27-Aug-2010
The recent government suspension of the manufacturing license for major flu vaccine maker Chiron in the UK has left many countries facing a severe shortage in flu vaccine supply for the 2004-05 season. In the light of previous vaccine provision difficulties, Datamonitor's Laura Harris argues that, in the longer term, cell culture vaccines could resolve the annual flu vaccine quandary...
On , the government announced it was to suspend the manufacturing license of California-based vaccines company Chiron, due to concerns about its manufacturing process. The news came soon after the company had announced a delay in shipment of four million doses since they did not meet sterility standards. Chiron, one of the world's largest vaccine companies with sales of $678 million in 2003, currently man…
On , the government announced it was to suspend the manufacturing license of California-based vaccines company Chiron, due to concerns about its manufacturing process. The news came soon after the company had announced a delay in shipment of four million doses since they did not meet sterility standards. Chiron, one of the world's largest vaccine companies with sales of $678 million in 2003, currently man…
27-Aug-2010
As with other emerging industrial sectors, the Indian pharmaceutical industry has made no secret of its desire to globalise and eventually compete with its foreign rivals.
As with other emerging industrial sectors, the Indian pharmaceutical industry has made no secret of its desire to globalise and eventually compete with its counterparts in Europe, Japan and the USA. This is an ambitious aim because most of the Indian industry's current success has been achieved in the area of generics rather than innovative new drugs, and its multinational competitors have decades more experience in global drug development and much greater financial power (1, 2). Incentives for R&D The Indian pharmaceutical industry has long campaigned for better incentives from the government to help them riv…
As with other emerging industrial sectors, the Indian pharmaceutical industry has made no secret of its desire to globalise and eventually compete with its counterparts in Europe, Japan and the USA. This is an ambitious aim because most of the Indian industry's current success has been achieved in the area of generics rather than innovative new drugs, and its multinational competitors have decades more experience in global drug development and much greater financial power (1, 2). Incentives for R&D The Indian pharmaceutical industry has long campaigned for better incentives from the government to help them riv…
27-Aug-2010
Last week, Merck & Co sent shockwaves through the pharmaceutical market with the announcement that it had voluntarily withdrawn its blockbuster arthritis drug Vioxx. Datamonitor's Adele Schulz examines the likely impact of this event, for the remainder of 2004 and beyond, on both Merck and its rivals...
In the days since Merck's action, speculation has been rife as to the implications for the remainder of the COX-2 market. What is certain is that existing pipeline products will be subjected to additional FDA scrutiny, most likely delaying the US launch of Novartis's Prexige (lumiracoxib) and Merck & Co.'s Arcoxia (etoricoxib), particularly as the emergence of Vioxx's (rofecoxib) cardiovascular side effects only occurred after 18 months means lengthy clinical trials are likely to be need…
In the days since Merck's action, speculation has been rife as to the implications for the remainder of the COX-2 market. What is certain is that existing pipeline products will be subjected to additional FDA scrutiny, most likely delaying the US launch of Novartis's Prexige (lumiracoxib) and Merck & Co.'s Arcoxia (etoricoxib), particularly as the emergence of Vioxx's (rofecoxib) cardiovascular side effects only occurred after 18 months means lengthy clinical trials are likely to be need…
The demographics of HIV patients are shifting, with the average age of those infected with HIV ever increasing due to longer life expectancy and higher survival rates. However, with increasingly complex infections and drug resistance developing in long term patients, novel medications and new combinations are now being launched to continue the fight...
Globally, the number of people living with HIV continues to grow from 35 million in 2001 to 38 million in 2003. An estimated 5 million people acquired HIV in 2003, the greatest number in any one year since the beginning of the epidemic, and in the same year almost three million died as a result of AIDS taking the total to 20 million since the first cases of AIDS were identified in 1981. The demographics of the HIV infected population is rapid…
Globally, the number of people living with HIV continues to grow from 35 million in 2001 to 38 million in 2003. An estimated 5 million people acquired HIV in 2003, the greatest number in any one year since the beginning of the epidemic, and in the same year almost three million died as a result of AIDS taking the total to 20 million since the first cases of AIDS were identified in 1981. The demographics of the HIV infected population is rapid…
Renal cell carcinoma (RCC) is a niche cancer that accounts for 2-3% of all solid tumors in the major pharmaceutical markets. Approximately 30,000 patients are diagnosed with the disease each year in the US and 12,000 patients die of the disease annually. The market is currently dominated by the cytokines, but there is significant interest among physicians in the potential of anti-angiogenics, particularly so since renal cell carcinomas are known to be well vascularized. Bayer's BAY 43-9006 is a
Renal cell carcinoma (RCC) is a niche cancer that accounts for 2-3% of all solid tumors in the major pharmaceutical markets. Approximately 30,000 patients are diagnosed with the disease each year in the and 12,000 patients die of the disease annually. The market is currently dominated by the cytoki…
Renal cell carcinoma (RCC) is a niche cancer that accounts for 2-3% of all solid tumors in the major pharmaceutical markets. Approximately 30,000 patients are diagnosed with the disease each year in the and 12,000 patients die of the disease annually. The market is currently dominated by the cytoki…
As the dust settles on Merck's withdrawal of Vioxx's, LeadDiscovery investigates the impact that this will have on the treatment of pain, R&D activity directed towards the identification of new approaches, and on pharmaceutical sales relating to COX-2 inhibitors and related drug classes
As hurricane season continues in the US, forces of a very different nature have blown through the pharmaceutical industry with Merck's withdrawal of the blockbuster Vioxx (Rofecoxib) from the market. This move was in response to new, three-year data from a prospective, randomized, placebo-controlled clinical trial, the APPROVe (Adenomatous Polyp Prevention on VIOXX) trial. The trial, which is being stopped, was designed to evaluate the efficacy of VIOXX in preventing recurrence of colorectal polyps in patien…
As hurricane season continues in the US, forces of a very different nature have blown through the pharmaceutical industry with Merck's withdrawal of the blockbuster Vioxx (Rofecoxib) from the market. This move was in response to new, three-year data from a prospective, randomized, placebo-controlled clinical trial, the APPROVe (Adenomatous Polyp Prevention on VIOXX) trial. The trial, which is being stopped, was designed to evaluate the efficacy of VIOXX in preventing recurrence of colorectal polyps in patien…
The market for Alzheimer's therapy is expected to grow from 16 million patients to 21 million by 2010 in the seven major pharmaceutical markets. Alzheimer's disease market in the seven major markets is worth $4.7 billion and will increase to $6.1 billion by the year 2005 and $ 7.8 billion by the year 2010. The major unmet need in this market is for disease modification and disease prevention. Recent findings by British researchers showing that targeting the neuronal adaptor protein X11beta can r
DailyUpdates 30th September, 2004: The pharmaceutical market for the treatment of neurodegenerative disorders will grow by an unprecedented amount over the next ten years. The aging of the baby-boom generation, combined with new and improved treatments for neurodegenerative disorders such as Alzheim…
DailyUpdates 30th September, 2004: The pharmaceutical market for the treatment of neurodegenerative disorders will grow by an unprecedented amount over the next ten years. The aging of the baby-boom generation, combined with new and improved treatments for neurodegenerative disorders such as Alzheim…
The pharmaceutical market for the treatment of neurodegenerative disorders will grow by an unprecedented amount over the next ten years. The aging of the baby-boom generation, combined with new and improved treatments for neurodegenerative disorders such as Alzheimer's and Parkinson's disease will lead to an expansion of the already $30 billion neurodegenerative market. Despite the growth of generic products, Parkinson's disease drug revenues grew an impressive 17% across the seven major markets
The pharmaceutical market for the treatment of neurodegenerative disorders will grow by an unprecedented amount over the next ten years. The aging of the baby-boom generation, combined with new and improved treatments for neurodegenerative disorders such as Alzheimer's and Parkinson's disease will l…
The pharmaceutical market for the treatment of neurodegenerative disorders will grow by an unprecedented amount over the next ten years. The aging of the baby-boom generation, combined with new and improved treatments for neurodegenerative disorders such as Alzheimer's and Parkinson's disease will l…
Earlier this year data was reported that Sankyo's angiotensin II receptor blocker (ARB) olmesartan medoxomil may offer improved anti-hypertensive activity when compared to other therapeutic agents within this highly competitive $31 billion market. More recently clinical data has appeared that shows olmesartan to have additional anti- inflammatory activity in hypertensive patients with vascular inflammation. This may confer additional therapeutic benefit since inflammation is an etiological compo
Earlier this year data was reported that Sankyo's angiotensin II receptor blocker (ARB) olmesartan medoxomil may offer improved anti-hypertensive activity when compared to other therapeutic agents within this highly competitive $31 billion market. More recently clinical data has appeared that shows…
Earlier this year data was reported that Sankyo's angiotensin II receptor blocker (ARB) olmesartan medoxomil may offer improved anti-hypertensive activity when compared to other therapeutic agents within this highly competitive $31 billion market. More recently clinical data has appeared that shows…
Early ejaculation represents a major market, and indeed in 18-65 year olds it represents the predominant sexual dysfunction, affecting at least 20% of men. The global annual market for the treatment of early ejaculation has been estimated at $4 billion. However due to the absence of readily available therapeutics fewer than 10% of patients seek treatment for early ejaculation. Successful pharmaceutical development in this field may therefore reap immense rewards. Drug development has however bee
Early ejaculation represents a major market, and indeed in 18-65 year olds it represents the predominant sexual dysfunction, affecting at least 20% of men. The global annual market for the treatment of early ejaculation has been estimated at $4 billion (for an analysis of male health care markets cl…
Early ejaculation represents a major market, and indeed in 18-65 year olds it represents the predominant sexual dysfunction, affecting at least 20% of men. The global annual market for the treatment of early ejaculation has been estimated at $4 billion (for an analysis of male health care markets cl…
It has been estimated that 9% of the US population suffers from moderate to severe non-cancer-related pain. Acute pain resulting from conditions such as headache, muscle spasms, dental problems or following surgery, affects 90 million Americans every year and the development of analgesics represents a major pharmaceutical objective. A recent study has demonstrated the analgesic activity of corticotropin-releasing-hormone (CRH) and has shown that this activity is probably due to activity within t
It has been estimated that 9% of the population suffers from moderate to severe non-cancer-related pain. Acute pain resulting from conditions such as headache, muscle spas, dental problems or following surgery, affects 90 million Americans every year. Chronic pain affects 40-70 million Americans an…
It has been estimated that 9% of the population suffers from moderate to severe non-cancer-related pain. Acute pain resulting from conditions such as headache, muscle spas, dental problems or following surgery, affects 90 million Americans every year. Chronic pain affects 40-70 million Americans an…
27-Aug-2010
Emerging Drug Discovery Targets provides a regular summary of some of the most exciting breaking information recently featured by the pharmaceutical analysts, LeadDiscovery. Information includes editorials on recently published journal articles, selected press releases and "intelligence reports". This edition features an LXA4 mimic for the treatment of inflammation; IL-27 as a cancer immunotherapy; anti-CD154 for organ transplant; CRH agonists for the treatment of pain; and an effective therapy
"Emerging Drug Discovery Targets" provides a regular summary of some of the most exciting breaking information recently featured by the pharmaceutical analysts, LeadDiscovery. Information includes editorials on recently published journal articles, selected press releases and "intelligence reports".…
"Emerging Drug Discovery Targets" provides a regular summary of some of the most exciting breaking information recently featured by the pharmaceutical analysts, LeadDiscovery. Information includes editorials on recently published journal articles, selected press releases and "intelligence reports".…
The recent success of monoclonal antibody therapies such as Genentech's Rituxan and Johnson & Johnson's Remicade are driving further development of this field. MAb therapies brought in revenues of over $5.1 billion in 2003, a figure which should nearly triple over the next five years as new MAbs are launched and following the approval of new indications for MAbs already on the market. By 2008, MAbs should account for 32 percent of all revenue in the biotech market. One therapeutic antibody indic
Since the first successful kidney transplantation more than 40 years ago, the treatment of end-stage organ failure has dramatically improved. Many organs are now transplanted, the most common of which include (procedures performed in the in 2001) the kidney (14,000), heart (2,000), liver (5,000) an…
Since the first successful kidney transplantation more than 40 years ago, the treatment of end-stage organ failure has dramatically improved. Many organs are now transplanted, the most common of which include (procedures performed in the in 2001) the kidney (14,000), heart (2,000), liver (5,000) an…
Treatments for inflammatory diseases comprise a $20 billion market spanning diseases such as psoriasis, asthma, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Both the prostaglandins and the leukotrienes are involved in the initiation and maintenance of inflammatory responses however agents that center on these mediators have produced limited therapeutic efficacy in various inflammatory disease settings. Harnessing the properties of anti-inflammatory mediators such as l
Treatments for inflammatory diseases comprise a $20 billion market that shows no signs of slowing in growth. Some of the most prevalent inflammatory diseases include psoriasis, asthma, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease (to view LeadDiscovery's feature on autoimm…
Treatments for inflammatory diseases comprise a $20 billion market that shows no signs of slowing in growth. Some of the most prevalent inflammatory diseases include psoriasis, asthma, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease (to view LeadDiscovery's feature on autoimm…
